Dermata Therapeutics, Inc.
DRMA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001853816
No open-market purchases or sales by Dermata Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $158.0K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Dermata Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Dermata Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Proehl Gerald T | PRESIDENT, CHAIRMAN, CEO | 292,631Indirect | Aug 18, 2026 | 3 |
| Van Hoose Kyri K. | SVP, CFO | 232,463 | Aug 18, 2026 | 3 |
| Scott Kathleen D. | Director | 0 | Jun 16, 2026 | 2 |
| Bedoya-Toro Munera Maria E | SVP, Regulatory Affairs | 1,012 | Mar 17, 2026 | 2 |
| Hale David F | Director | 80,957Indirect | Jan 6, 2026 | 1 |
| Wierenga Wendell | Director | 62,398 | Jan 6, 2026 | 1 |
| Fisher Mary | Director | 196,946 | Jan 6, 2026 | 1 |
| Mento Steven J | Director | – | Jan 6, 2026 | 1 |
| Sandler Andrew Seth | Director | 24,184 | Jan 6, 2026 | 1 |
| Nardo Christopher J. | Senior VP, CDO | 2,439Indirect | Jan 6, 2026 | 1 |
| Bradrick Brittany | Director | 23,443 | Jan 6, 2026 | 1 |
| Insley Thomas | Chief Financial Officer | 14,337Indirect | Aug 17, 2021 | 0 |
| Proehl Investment Ventures LLC | 10% Owner | 2,905,544 | Aug 17, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 (view filing) | Jun 16 | Same day | Scott Kathleen D.Director | SSale | −11 | $1.19 | −$13.09 | −100.0%0 after | |
| Mar 17, 2026 (view filing) | Feb 17 | 28 daysLate | Bedoya-Toro Munera Maria ESVP, Regulatory Affairs | PPurchase | +1.00K | $1.27 | +$1.27K | +8,333.3%1.01K after | |
| Nov 26, 2021 (view filing) | Nov 23 | 3 days | Proehl Gerald TPresident, CEO and Chairman | PPurchase | +20.0K | $2.40 | +$48.0K | +50.6%59.5K after | |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Hale David FDirector, 10% Owner | PPurchase | +35.7K | – | – | New position35.7K after | |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Hale David FDirector, 10% Owner | PPurchase | +35.7K | – | – | –35.7K after | Derivative |
| Aug 17, 2021 (view filing) | Aug 16-17 | 1 day | Proehl Gerald TPresident, CEO and Chairman | PPurchase | +152.9K | $4.96 | +$49.6K | New position152.9K after | 2 lots |
| Aug 17, 2021 (view filing) | Aug 17 | Same day | Proehl Gerald TPresident, CEO and Chairman | PPurchase | +142.9K | – | – | –142.9K after | Derivative |